Shanghai InnoStar Bio-tech Co

Shanghai InnoStar Bio-tech Co FCF Growth

The Year-over-Year Free Cash Flow Growth of Shanghai InnoStar Bio-tech Co (688710.SS) as of Oct 20, 2026 is 91.52 %. In the previous year, Year-over-Year Free Cash Flow Growth was -483.38 % — a change of -118.93% (higher).

FCF Growth

91.52 %

YoY

-118.93%

Last updated:

Year-over-Year Free Cash Flow Growth of Shanghai InnoStar Bio-tech Co is 2025 91.52 % . Year-over-Year Free Cash Flow Growth of Shanghai InnoStar Bio-tech Co was 2024 -483.38 % . It decreases by -118.93% higher compared to the previous year.

The Shanghai InnoStar Bio-tech Co FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2022
199.32 CNY
Jan 1, 2023
-149.63 CNY
Jan 1, 2024
-483.38 CNY
Jan 1, 2025
91.52 CNY
The Shanghai InnoStar Bio-tech Co FCF Growth history
YEARFCF GrowthYoY
91.52 %-118.93%
-483.38 %+223.04%
-149.63 %-175.07%
199.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai InnoStar Bio-tech Co Stock analysis

What does Shanghai InnoStar Bio-tech Co do? Shanghai InnoStar Bio-tech Co Ltd generates revenue through biopharmaceutical non-clinical research services, primarily targeting pharmaceutical companies and biotech firms. The company offers early drug development evaluation services that develop multiple early toxicity rapid prediction and screening models. Non-clinical research services include non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacodynamic research. Clinical testing and translational research provides analytical methods and data support for clinical pharmacokinetics, efficacy, and safety research of innovative drug projects. The firm's clients are pharmaceutical companies and biotech firms seeking to advance innovative drug projects through non-clinical and clinical research. These clients purchase the company's services to support early drug development, safety evaluation, and translational research needs. The company's focus on biopharmaceutical non-clinical research positions it to serve the growing demand for specialized research services in the life sciences sector. Shanghai InnoStar Bio-tech Co Ltd's service portfolio is structured around three core areas: early drug development evaluation, non-clinical research, and clinical testing and translational research. Each segment provides specialized services that support different stages of drug development, from initial toxicity screening to clinical research support. The company's revenue is derived from these specialized service offerings delivered to pharmaceutical and biotech clients. Shanghai InnoStar Bio-tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai InnoStar Bio-tech Co stock

Year-over-Year Free Cash Flow Growth of Shanghai InnoStar Bio-tech Co is 91.52 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Shanghai InnoStar Bio-tech Co since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Shanghai InnoStar Bio-tech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Shanghai InnoStar Bio-tech Co

All Key Metrics — Shanghai InnoStar Bio-tech Co